Financial Data and Key Metrics Changes - The company reported a steady increase in the number of franchisee clinics, reaching 258, with a 34-location increase, and the annual customer count expanded to approximately 6.5 million [2] - Financial performance showed signs of recovery, with sales previously affected by restructuring and franchise fees, but now supported by an increase in point-related revenues [3] - Operating income and net income improved due to a decline in racing-related costs, including share-based compensation expenses [3] Business Line Data and Key Metrics Changes - The average revenue per customer visit is recovering due to pricing and promotion initiatives, as well as a multi-brand strategy in the dermatology segment [3] - The company is focusing on enhancing R&D and expanding unique service offerings through the acquisition of Waku, which specializes in regenerative medicine and skincare products [4][5] Market Data and Key Metrics Changes - The company has entered into a partnership with BLEZ ASIA to provide laser treatment in Thailand, aiming to tap into the growing aesthetic medical market [4] - The financial impact of the new BREATH initiative in Thailand is expected to be minimal in the near term, with plans to expand into other Asian countries after proof of concept [10] Company Strategy and Development Direction - The company aims to strengthen its overall competitiveness and achieve sustainable growth through strategic acquisitions and partnerships, particularly in the aesthetic medical field [5][20] - The M&A strategy is divided into domestic and global perspectives, focusing on clinic field acquisitions in Japan and exploring investment opportunities in the US market [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about maintaining the positive momentum observed in Q3, with expectations for stable financial performance in Q4 and the following year [11][22] - The company is considering providing financial guidance in the near future to address investor needs for revenue and profit expectations [22][26] Other Important Information - The company is working on improving share liquidity through new share issuance and potential share buybacks, acknowledging that the current share price is too low [6][24] - Dividend payments are being considered as a way to attract new investors, although the company prioritizes capital allocation towards strategic initiatives [25] Q&A Session Summary Question: Why was COVID elevated during Q3 2025, and when do you expect a franchise fee division impact to be fully absorbed going forward? - The increase in costs was attributed to medical equipment lease and the consolidation of AHH acquired in Singapore, with financial performance expected to continue improving [8] Question: Could you elaborate on the balance sheet changes during the quarter? - Changes included borrowing for working capital, adjustments in payment terms for related parties, and a decrease in tax debt due to midterm income tax payments [9] Question: What is the expected impact of the new BREATH initiative in Thailand? - The near-term financial impact will be minimal as the company conducts proof of concept for laser treatments, with plans for future expansion into other Asian markets [10] Question: What is the expectation for organic growth going forward? - The company anticipates maintaining the positive momentum from Q3, with expectations for stable financial performance in the upcoming quarters [11] Question: Can you describe the strategic relationship behind acquiring Waku? - The acquisition aims to realize synergies through enhanced sales of Waku products at SBC clinics and joint development of pharmaceutical and medical devices [12][15] Question: Can you comment on the latest status of US business development efforts? - The company is in the phase of understanding the US market and seeking strong partners to leverage its strengths from Japan, with cautious plans for future clinic development [17][18] Question: What are the expectations for M&A going forward? - The M&A strategy will focus on domestic clinic acquisitions and exploring investment opportunities in the global market, particularly in the US [20] Question: How do you plan to improve the liquidity situation? - Plans include increasing free float through new share issuance and potential share buybacks, acknowledging the current low share price [24] Question: Do you think about the dividend going forward? - Dividend payments are considered to attract new investors, but the company prioritizes capital allocation towards growth opportunities [25] Question: Do you have any plan to disclose financial guidance going forward? - The company is considering providing financial guidance in the near future [26]

Financial Data and Key Metrics Changes - The company reported a steady increase in the number of franchisee clinics, reaching 258 clinics, with an annual customer base expanding to approximately 6.5 million [2][3] - Financial performance showed signs of recovery, with operating income and net income benefiting from a decline in racing-related costs and an increase in point-related revenues [3][4] Business Line Data and Key Metrics Changes - The average revenue per customer visit is recovering due to pricing and promotion strategies, as well as a multi-brand strategy in the dermatology segment [3] - The company is focusing on enhancing R&D capabilities through the acquisition of Waku, which specializes in regenerative medicine and skincare products [4][5] Market Data and Key Metrics Changes - The company has entered into a partnership with BLEZ ASIA to provide laser treatment in Thailand, aiming to tap into the growing aesthetic medical market [4] - The company is exploring proof of concept (POC) initiatives in Thailand, with plans to expand into other Asian markets like Malaysia and Indonesia [11] Company Strategy and Development Direction - The company aims to strengthen its overall competitiveness and achieve sustainable growth through strategic partnerships and acquisitions, particularly in the aesthetic medical and clinical industries [20] - The U.S. market entry strategy involves forming strong partnerships and leveraging learnings from the Japanese market, while being cautious about direct replication of the business model [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about maintaining positive momentum in financial performance, expecting stable growth in Q4 and the following year [12][21] - The company is considering providing financial guidance in the near future to address investor needs for revenue and profit expectations [21][25] Other Important Information - The company is working on improving liquidity through measures such as new share issuance and potential share buybacks, acknowledging the current low share price [6][23] - Dividend payments are being considered as a way to attract new investors, although the focus remains on capital allocation for strategic initiatives [24] Q&A Session Summary Question: Why was COVID elevated during Q3 2025, and when do you expect a Franchise Fee Division impact to be fully absorbed going forward? - The increase in costs was attributed to medical equipment lease and the consolidation of AHH acquired in Singapore, with expectations of continued positive trends [9] Question: Could you elaborate on the Balance Sheet changes during the quarter? - Changes included borrowing for working capital, adjustments in payment terms for related parties, and a decrease in tax debt due to midterm income tax payments [10] Question: What is your expectation for organic growth going forward for both breadth and revenue? - The company expects to maintain positive momentum seen in Q3, with stable financial performance anticipated in Q4 and next year [12] Question: Could you describe the strategic relationship behind acquiring Waku? - The acquisition aims to realize synergies through enhanced sales of Waku products at SBC clinics and joint development of pharmaceutical and medical devices [15][16] Question: Can you comment on the latest status of your U.S. business development efforts? - The company is in a phase of understanding the U.S. market and seeking strong partners, with plans for future growth and expansion once comfortable [17][18] Question: What do you mean by more stable financial performance in Q4 and 2026? - Management confirmed expectations for revenue growth but could not provide specific numbers at this time [21] Question: How do you think about improving the liquidity situation? - The company is considering new share issues and share buybacks to increase free float and address low share prices [23] Question: Do you have any plan to disclose financial guidance or performance guidance going forward? - The company is actively considering providing financial guidance in the near future [25]

Financial Data and Key Metrics Changes - The company reported total client assets of BRL 1.9 trillion, reflecting a 16% year-over-year growth [4] - Gross revenues reached BRL 4.9 billion, representing a 9% growth year over year [19] - Earnings Before Tax (EBT) increased by 10% year over year to BRL 1.3 billion [23] - The company achieved a Return on Equity (ROE) of 23%, remaining flat year over year [7] - Diluted Earnings Per Share (EPS) grew by 13% year over year, reaching BRL 2.47 [25] Business Line Data and Key Metrics Changes - Retail revenues amounted to BRL 3.7 billion, showing a 6% growth year over year [19] - Corporate and industry services achieved a record revenue of BRL 729 million, with a 32% year-over-year growth [21] - Life insurance retail premiums grew by 25% year over year [14] - Credit revenues posted an 11% growth year over year, reaching BRL 83 million in Net Interest Income (NII) [14] Market Data and Key Metrics Changes - The company reported BRL 20 billion in retail net new money, which was three times higher than the previous quarter but BRL 5 billion lower than last year [8] - The company maintained a 10% market share in capital markets distribution [15] - The wholesale banking segment showed strong performance, with expectations for continued growth in the fourth quarter [31] Company Strategy and Development Direction - The company aims to become the leader in investments in Brazil by enhancing client service and introducing new products [3] - A focus on high-quality wealth planning services for clients with varying asset levels is part of the strategy [10] - The company is transitioning to a fee-based model, which currently accounts for 21% of total retail Assets Under Custody (AUC) [11] - The company is committed to investing in technology and expanding its sales force to enhance client experience [22] Management's Comments on Operating Environment and Future Outlook - The management acknowledged the challenges faced in 2025 but emphasized the commitment to evolving the business for growth and profitability [4] - The management expressed confidence in achieving a target of around BRL 20 billion in retail net new money per quarter [8] - The company anticipates a volatile market in 2026, which may present opportunities for growth [70] Other Important Information - The company repurchased BRL 2 billion in shares in 2025, with a new buyback program of BRL 1 billion announced [24] - A dividend of BRL 500 million is planned for 2025, representing a 50% payout ratio based on net income [24] Q&A Session Summary Question: Expectations for wholesale business performance in Q4 - Management expects continued strong performance in the wholesale banking segment for Q4, with a focus on high-quality assets [31][33] Question: Clarification on corporate revenues and hedging strategy - Corporate revenues are tied to debt issuance and hedging solutions, with expectations for continued strength due to low credit spreads [76] Question: Insights on retail revenue growth and fixed income performance - Fixed income revenues contracted due to a shift in product mix towards lower take rates, while retail revenues grew overall [43][46] Question: Impact of new hires on advisor numbers - The company is hiring more internal advisors while converting some independent financial advisors (IFAs) to employees, focusing on quality over quantity [52] Question: Financial expenses and borrowing reductions - The reduction in financial expenses is attributed to a geographic shift in debt management, resulting in lower overall costs [53] Question: Guidance on EBT margin and revenue expectations - Management remains optimistic about achieving medium-term guidance for EBT margins, despite potential shortfalls in revenue growth [84]

Financial Data and Key Metrics Changes - The company achieved a positive adjusted EBITDA of nearly $500,000 for the first time in its history, marking a significant financial milestone [3] - Cash generated from operations was over $250,000, indicating a shift towards financial independence [3] - Q3 revenue reached $6.8 million, a 30% increase year-over-year and a 20% increase quarter-over-quarter [7] - Adjusted EBITDA improved to $469,000 compared to $100,000 a year ago and a loss of $78,000 in the previous quarter [17] - Cash from operations showed a positive swing of $433,000, moving from a cash burn of $148,000 in Q2 to a cash generation of $285,000 in Q3 [17] Business Line Data and Key Metrics Changes - The Pathology Services Division generated $6 million in Q3, a 20% increase from $5 million in Q2, driven by new customer acquisitions [8] - Gross margin for the Pathology Services Division improved from 43% to 46% due to efficient operations [17] - The Products Division saw a 16% quarter-over-quarter growth, increasing from approximately $620,000 in Q2 to $720,000 in Q3 [10] - Overall gross margins improved slightly from 43% to 44%, with expectations for continued upward trends as both divisions grow [11] Market Data and Key Metrics Changes - The company’s share price has tripled since the beginning of 2025, reflecting market confidence in its financial performance [5] - The company is experiencing a strong sales funnel with several new customers in trial phases, indicating potential for future growth [8] Company Strategy and Development Direction - The company is transitioning from a defensive to an offensive strategy, focusing on reinvesting cash generated into growth initiatives [3][5] - Plans include driving double-digit growth in both divisions, expanding margins, and increasing liquidity and share price appreciation [19] - The company aims to leverage its financial independence to explore strategic partnerships and innovative products [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company’s ability to grow organically without reliance on outside capital, marking a significant operational threshold [18] - The focus is on maintaining a culture of accountability, collaboration, and customer empathy to support sustained growth [9] - Future priorities include continued growth, margin expansion, and strategic reinvestment to enhance market position [19] Other Important Information - The company is nearing the completion of its full repayment of Change Healthcare, which will free up cash generated from operations starting in Q1 2026 [18] - The company has made strategic investments in lab space and technical support to enhance operational efficiency and customer onboarding [12][15] Q&A Session Summary - No specific questions or answers were provided in the content, indicating that the conference call concluded without a Q&A segment [21]

Financial Data and Key Metrics Changes - For Q3 2025, the company achieved a positive adjusted EBITDA of nearly $500,000 and generated over $250,000 in cash from operations, marking a significant financial milestone [3][15] - Revenue for Q3 reached $6.8 million, representing a 30% increase year-over-year and a 20% increase quarter-over-quarter [6] - Adjusted EBITDA improved to $469,000 compared to $100,000 a year ago and a loss of $78,000 in Q2 2025, indicating a swing of over $500,000 in just one quarter [15] - Cash generated from operations was $285,000, a positive cash swing of $433,000 compared to a cash burn of $148,000 in the previous quarter [15] Business Line Data and Key Metrics Changes - The Pathology Services Division reported revenue growth from $5 million in Q2 to $6 million in Q3, a 20% increase, driven by new customer acquisitions [7] - The Products Division experienced a 16% quarter-over-quarter growth, increasing from approximately $620,000 in Q2 to $720,000 in Q3, primarily due to increased utilization from existing customers and new product introductions [9][10] - Gross margins improved from 43% to 44% overall, with the Pathology Services Division increasing margins from 43% to 46% [10][15] Market Data and Key Metrics Changes - The company has seen a tripling of its share price since the beginning of 2023, reflecting market confidence in its financial performance and growth strategy [5] - The company is experiencing a strong sales funnel with several new customers in trial phases, indicating a robust market demand for its services [7] Company Strategy and Development Direction - The company is transitioning from a defensive to an offensive strategy, focusing on reinvesting cash generated from operations to accelerate growth [3][5] - Future priorities include driving double-digit growth in both divisions, expanding margins, and reinvesting cash into growth initiatives [17] - The company aims to achieve a gross margin exceeding 50% by mid-2026 as both divisions scale up [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's self-sustaining business model, stating that it will no longer depend on outside capital for operations [16] - The company anticipates that increased market capitalization will present new strategic opportunities for growth and partnerships [16] - Management emphasized the importance of their mission, linking financial success to improved patient care outcomes [17] Other Important Information - The company is nearing the completion of its full repayment of Change Healthcare, which will free up cash generated from operations starting in Q1 2026 [16] - The company has made strategic investments in lab space and technical support to enhance operational efficiency and customer onboarding [11][14] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Financial Data and Key Metrics Changes - The company reported total client assets of BRL 1.9 trillion, reflecting a 16% year-over-year growth [4] - Gross revenues reached BRL 4.9 billion, representing a 9% growth year over year [5][18] - EBIT increased by 10% year over year to BRL 1.3 billion [5] - The return on equity (ROE) was 23%, remaining flat year over year [6] - Diluted EPS grew by 13% year over year, reaching BRL 2.47 per share [24] Business Line Data and Key Metrics Changes - Retail revenues amounted to BRL 3.7 billion, showing a 6% growth year over year [18] - Corporate and industry services achieved a record BRL 729 million in revenues, marking a 32% growth year over year [18] - Life insurance retail premiums grew by 25% year over year [13] - Credit revenues increased by 11% year over year, reaching BRL 83 million in net interest income [13] Market Data and Key Metrics Changes - Retail net new money was BRL 20 billion, a decrease of BRL 5 billion compared to the previous year but three times higher than the last quarter [7] - The company maintained a 10% market share in capital markets distribution [15] - The wholesale bank maintained a leadership position with a 17% market share [16] Company Strategy and Development Direction - The company aims to become the leader in investments in Brazil by enhancing client service and introducing new products [3][10] - A focus on high-quality wealth planning services for clients with varying asset levels is being emphasized [10] - The company is transitioning to a fee-based model, which currently accounts for 21% of total retail assets under custody [11] Management's Comments on Operating Environment and Future Outlook - The management acknowledged the challenges faced in 2025 but expressed commitment to evolving the business for growth and profitability [4] - The company anticipates continued growth in retail net new money, targeting around BRL 20 billion per quarter [9] - Management highlighted the importance of maintaining a conservative risk profile despite strong performance in wholesale banking [25] Other Important Information - The company repurchased BRL 2 billion in shares in 2025, with a new buyback program of BRL 1 billion announced [23] - A dividend of BRL 500 million is planned for 2025, representing a 50% payout ratio based on net income [23] Q&A Session Summary Question: Expectations for wholesale business performance in Q4 - Management expects good performance in Q4, with stronger results anticipated compared to the first half of the year [26][27] Question: Details on the strategy to increase the warehousing book - The strategy involves holding high-quality assets and managing credit spread volatility effectively [27] Question: Clarification on corporate revenue increase - Corporate revenues are closely tied to debt issuance and hedging solutions, with strong performance expected to continue [30][44] Question: Insights on retail revenue growth despite fixed income contraction - The contraction in fixed income revenues is attributed to a shift in product mix and shorter durations affecting take rates [31][33] Question: Impact of workdays on revenues - Business days positively impacted floating and trading volumes, offsetting declines in equities and fixed income [49] Question: Use of AI in client advisory services - The company is leveraging AI to enhance advisor productivity and improve client service, particularly for lower-income clients [51]

Financial Data and Key Metrics Changes - The company reported a steady increase in the number of franchisee clinics, reaching 258, with a 34-location increase, and the annual customer count expanded to approximately 6.5 million [2] - Financial performance showed signs of recovery, with sales previously affected by restructuring and franchise fee division, but now supported by an increase in point-related revenues [3][4] - The decline in racing-related costs, including share-based compensation expenses, contributed to improvements in both operating income and net income [3] Business Line Data and Key Metrics Changes - The average revenue per customer visit is showing signs of recovery due to pricing and promotion initiatives, as well as a multi-brand strategy in the dermatology segment [3] - The company is focusing on enhancing R&D and expanding service offerings through the acquisition of Waku, which specializes in regenerative medicine and skincare products [4][5] Market Data and Key Metrics Changes - The company has entered into a partnership with BLEZ ASIA to provide laser treatment in Thailand, aiming to tap into the growing aesthetic medical market [4] - The financial impact of the new BREATH initiative in Thailand is expected to be minimal in the near term as the company conducts proof of concept trials [10] Company Strategy and Development Direction - The company aims to strengthen its competitiveness and achieve sustainable growth through strategic acquisitions and partnerships, particularly in the aesthetic medical field [5][20] - The M&A strategy is divided into domestic and global perspectives, focusing on clinic acquisitions in Japan and exploring investments in the global market, especially in the US [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about maintaining the positive momentum observed in Q3 2025, with expectations for stable financial performance in Q4 and 2026 [11][22] - The company is considering providing financial guidance in the near future to address investor needs for revenue and profit expectations [22][26] Other Important Information - The company is working on improving liquidity by increasing free float shares and considering new share issuances and share buybacks [24] - Dividend payments are being considered as a way to attract new investors, although the company prioritizes capital allocation towards strategic initiatives [25] Q&A Session Summary Question: Why was COVID elevated during Q3 2025, and when do you expect a franchise fee division impact to be fully absorbed going forward? - The increase in costs was attributed to medical equipment lease and the consolidation of AHH acquired in Singapore, with financial performance expected to continue improving [8] Question: Could you elaborate on the balance sheet changes during the quarter? - Changes included borrowing for working capital, adjustments in payment terms for related parties, and a decrease in tax debt due to midterm income tax payments [9] Question: What is your expectation for organic growth going forward for both breadth and revenue? - The company expects to maintain the positive momentum seen in Q3, with more stable financial performance anticipated in Q4 and next year [11] Question: Can you describe the strategic relationship behind acquiring Waku? - The acquisition aims to realize synergies through strengthening sales of Waku products at SBC clinics and jointly developing pharmaceutical and medical devices [12][14] Question: Can you comment on the latest status of your US business development efforts? - The company is in the phase of understanding the US market and seeking strong partners to leverage its strengths from Japan [17] Question: What do you mean by more stable financial performance in Q4 and 2026? - Management confirmed expectations for a return to revenue growth but could not provide specific numbers at this time [22] Question: How do you think about improving the liquidity situation? - The company aims to increase free float shares and is considering share buybacks due to the current low share price [24] Question: Do you have any plan to disclose financial guidance or performance guidance going forward? - The company is actively considering providing financial guidance in the near future [26]

Financial Data and Key Metrics Changes - For the first quarter of fiscal 2026, the company reported revenue of CAD 19.2 million, an increase of approximately 27% compared to CAD 15.1 million in the same period last year [11][12] - Gross margin improved significantly from 27% to 45% year-over-year [12][27] - Net income for the quarter was CAD 1 million or CAD 0.03 per basic share, compared to a net loss of CAD 26.5 million or CAD 0.87 per basic share in the same quarter of fiscal 2025 [13] Business Line Data and Key Metrics Changes - Development fee revenue for Q1 fiscal 2026 was CAD 3.4 million, a notable increase from zero in the same period last year, reflecting higher development activities [11][12] - Revenue from EPC services increased slightly to CAD 11.9 million, up approximately 1% from the prior year [11] - Independent Power Producer (IPP) revenue grew to CAD 3.8 million, an 18% increase from CAD 3.3 million in the prior fiscal year [5][12] Market Data and Key Metrics Changes - The company is currently managing projects representing approximately 104 MW of solar and 44 MWh of battery energy storage expected to reach notice to proceed within 12 months [4] - The company has announced several projects in the U.S. and Canada, including a fully operational 3.8 MW solar power plant in New York and a 4.99 MW battery energy storage system in Ontario [6][9] Company Strategy and Development Direction - The company is focusing on expanding its IPP portfolio and advancing its development pipelines, particularly in battery storage project development [15][18] - The company is also entering the data center market and exploring environmentally friendly solutions for data centers powered by solar energy [20][21] - A strategic development agreement has been established with Intellistic Technologies to integrate AI and blockchain technologies into the company's operations [23] Management's Comments on Operating Environment and Future Outlook - Management noted that the renewable energy industry has faced significant headwinds but sees a clearer path forward due to supportive government policies [16][17] - The demand for battery storage is expected to increase due to rising electricity prices and the need for power reliability [32] - The company remains optimistic about the future of battery storage and solar energy, citing technological advancements and cost reductions [20][32] Other Important Information - The company has secured favorable financing terms and continues to maintain a strong cash position of approximately CAD 13.3 million [15] - The company is actively engaging with local communities to address concerns related to battery storage projects, which has caused some permitting delays [30][31] Q&A Session Summary Question: Factors driving the company's gross margin increase from 27% to 45% - Management attributed the increase to effective field management and procurement strategies, noting that the company has shifted to domestic procurement to maintain cost advantages [26][27] Question: Delays impacting key projects and outlook - Management acknowledged permitting delays for the SFFO6 project and interconnection challenges for other projects, but remains positive about the battery storage market due to increasing demand and electricity prices [29][32] Question: Progress in monetizing and securing safe harbor for US pipelines - Management indicated that the company is focusing on project-specific long lead items to meet new guidelines and ensure timely project delivery [34][35]

Financial Data and Key Metrics Changes - For the first quarter of fiscal 2026, the company reported revenue of CAD 19.2 million, an increase of approximately 27% compared to CAD 15.1 million in the same period last year [11] - Gross margin improved significantly to approximately 45% from 27% in the same quarter last year [12] - Net income for the quarter was around CAD 1 million or CAD 0.03 per basic share, compared to a net loss of CAD 26.5 million or CAD 0.87 per basic share in the same quarter of fiscal 2025 [13] Business Line Data and Key Metrics Changes - Development fee revenue for Q1 fiscal 2026 was CAD 3.4 million, reflecting higher development activities, whereas no development fee revenue was recorded in the same period last year [11] - Revenue from EPC services increased by approximately 1% to CAD 11.9 million in the first quarter [12] - Independent Power Producer (IPP) revenue grew to CAD 3.8 million, up from CAD 3.3 million in the prior year, marking an 18% increase [5][12] Market Data and Key Metrics Changes - The company is focusing on expanding its IPP portfolio and advancing development pipelines, particularly in the U.S. and Canada [15] - The demand for battery storage is increasing, with the company shifting marketing and sales activities towards battery storage project development [18] Company Strategy and Development Direction - The company aims to deliver a significant number of solar projects before the end of 2030, leveraging U.S. government guidance and incentives [17] - The company is entering the data center market and exploring environmentally friendly solutions for data centers powered by solar energy [20][21] - A strategic development agreement has been established with Intellistic Technologies to focus on AI and blockchain technologies [23] Management's Comments on Operating Environment and Future Outlook - The management acknowledges challenges in the renewable energy industry over the past year but sees a clearer path forward due to supportive government policies [16] - The company remains positive about the outlook for battery storage, citing increasing electricity prices and demand for reliable power solutions [32] Other Important Information - The company has secured contracts for various solar projects in New York and Nova Scotia, indicating a strong project pipeline [8][9] - The company is also exploring a Crypto Treasury Strategy using revenue from its solar assets [22] Q&A Session Summary Question: Factors driving the company's gross margin increase from 27% to 45% - The increase is attributed to effective management of field activities and procurement strategies, shifting from international to domestic content [26][27] Question: Delays impacting key projects and outlook for the market - Delays are primarily due to permitting issues and interconnection challenges, but the company remains optimistic about the battery storage market [29][32] Question: Progress in monetizing and securing safe harbor for US pipelines - The company is focusing on project-specific long lead items to meet new guidelines and ensure timely project delivery [34][35]

Financial Data and Key Metrics Changes - Consolidated revenue grew 13% year-over-year to $60.2 million, with telehealth revenue increasing 18% to $47.3 million [18][19] - Adjusted EBITDA increased 30% compared to the prior year, totaling $5.1 million for the third quarter [19][21] - Gross margin for the third quarter was 88%, a decline of 290 basis points year-over-year due to revenue mix [18][19] Business Line Data and Key Metrics Changes - The RexMD business added approximately 10,000 net new subscribers, rebounding from previous lows [4][17] - Weight management remains over 50% of the company's total revenue mix, although there was a slight sequential decline in subscriber base [24][25] - Demand for personalized ED medications represented 25% of all new ED prescriptions on the RexMD platform [10] Market Data and Key Metrics Changes - LifeMD is positioned to be a leading virtual destination for high-quality care, with over 130 million Americans eligible for treatment [9] - The company expects to offer oral GLP-1 medications, which could significantly broaden access and reshape the market landscape [9][56] Company Strategy and Development Direction - Strategic priorities for 2026 include accelerating growth in weight management, scaling women's and behavioral health businesses, and launching a unified LifeMD platform [6][15] - The company aims to leverage collaborations with Novo Nordisk and Eli Lilly to enhance its competitive advantage in the GLP-1 space [7][8] - LifeMD plans to invest in growth for women's health and behavioral health offerings, which are expected to become significant revenue streams [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026, anticipating significant growth driven by better pricing for branded therapies and increased insurance coverage [28][34] - The competitive landscape in the weight management category has intensified, but LifeMD remains focused on high-quality offerings [7][56] - The anticipated approval of the Wegovy pill is expected to be a major catalyst for business growth [9][56] Other Important Information - The company divested its majority interest in WorkSimpli, strengthening its balance sheet and allowing it to focus on its core healthcare platform [5][17] - LifeMD has secured regulatory approval for its non-sterile 503A compounding pharmacy, which will enhance its ability to produce personalized medications [5][11] Q&A Session Summary Question: Can you talk about the mix of telehealth product revenue, especially in weight loss? - Weight management still constitutes more than 50% of total revenue, with a slight sequential decline in subscriber base [24][25] Question: What portion of your revenue is insurance-covered versus cash-pay? - Management is not prepared to provide an exact percentage but noted that a significant portion of patients do not continue due to lack of insurance coverage [34][37] Question: How much of the growth in RexMD is driven by men's HRT versus ED? - About 8,000 of the 10,000 new members came from the sexual health business, primarily ED [61] Question: What drove the decline in telehealth gross margin? - The decline was attributed to a shift towards branded products, which do not carry the same fulfillment fees as personalized compounds [62][63] Question: What impact do you expect from the new consumer-facing app and website? - The new app is expected to significantly enhance cross-selling ability and improve customer retention [75][76] Question: What is the anticipated timeline for reaching 50-state coverage for the 503A pharmacy? - The company expects to be licensed in 35 states within 60-90 days and aims for full coverage shortly thereafter [80][81]